Skip to content

Maren Hermanns‐clausen

5 papers in the library · 52 citations · publishing 2016-2026

Papers

Sort Most recent Most cited

An ETH-LAD trip with unfavourable consequences: A case report.

British Journal of Clinical Pharmacology August 7, 2026 J. Nadler, Michaela J. Sommer, Annette Zschiesche et al.

Numerous analogues of the psychedelic and internationally controlled hallucinogen LSD have been described; however, only a limited number have been systematically investigated. This report presents the first case with an analytically confirmed ingestion of ETH-LAD (6-ethyl-6-nor-lysergic acid diethylamide), the N-ethyl derivative of LSD. An adolescent patient developed moderate to severe...

Recreational drug poisonings reported to six European poison centres from 2021 to 2024

Clinical Toxicology March 4, 2026 Laura Hondebrink, Katrin Faber, Aza Kader et al. 1 citation

INTRODUCTION: Recreational drug poisonings pose a growing public health concern. European-level data remain limited, although poison centres are well placed to monitor related health incidents. This study analysed temporal trends in recreational drug poisonings reported to six European poison centres. METHODS: Aggregated retrospective data were collected over four years (2021-2024) from poison...

Validation of an LC-MS/MS method for the quantitative analysis of 1P-LSD and its tentative metabolite LSD in fortified urine and serum samples including stability tests for 1P-LSD under different storage conditions

Journal of Pharmaceutical and Biomedical Analysis May 28, 2019 Christina Grumann, Kerstin Henkel, Alexander Stratford et al. 27 citations

A variety of hallucinogens of the lysergamide type has emerged on the drug market in recent years and one such uncontrolled derivative of lysergic acid diethylamide (LSD) is 1-propionyl-LSD (1P-LSD). Due to the high potency of LSD and some of its derivatives (common doses: 50-200 μg), sensitive methods are required for the analysis of biological samples such as serum and urine. The occurrence...

Bad trip due to 25I-NBOMe: a case report from the EU project SPICE II plus.

Clinical toxicology (Philadelphia, Pa.) September 1, 2017 Maren Hermanns‐clausen, Verena Angerer, Josephine Kithinji et al. 22 citations

The potent hallucinogenic drug 25I-NBOMe has recently emerged on the drug market. We present a case with analytically confirmed 25I-NBOMe intoxication from the prospective study "SPICE II Plus". Because of a severe headache a 42-year-old man took one sip of a pediatric analgesic syrup, which had been refilled with a self-made solution of 25I-NBOMe in ethanol. Thirty minutes later restlessness...

Entwicklung des Missbrauchs psychotroper Pflanzen und Pilze in Deutschland – Interpretation der Zahlen aus 3 Giftinformationszentren für die Jahre 2007–2013

Das Gesundheitswesen June 14, 2016 Jörg Pietsch, K. Scheffel, Daniela Acquarone et al. 2 citations

AIM OF THE STUDY: Based on an abundance of information on the internet, psychotropic plants and mushrooms are of increasing relevance as legal and cheap alternatives to other illicit drugs. Due to the lack of a German database, the abuse of selected biogenic drugs using reported exposures to 3 German Poison Information Centres (PICs) was examined. METHODS: Information on abuse of biogenic drugs...